Je­re­my Levin joins the biotech IPO rush, gain­ing $75M for Ovid’s R&D game plan

Je­re­my Levin is once again run­ning a pub­lic com­pa­ny. His start­up Ovid Ther­a­peu­tics $OVID has suc­cess­ful­ly launched an IPO, rais­ing $75 mil­lion af­ter sell­ing 5 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.